ESPScientists at Mount Sinai have unveiled a bold new way to fight metastatic cancer by turning the tumor’s own defenses against it. Instead of attacking cancer cells head-on, the experimental immunotherapy targets macrophages—immune cells that tumors hijack to shield themselves from attack. By eliminating or reprogramming these “bodyguards,” the treatment cracks open the tumor’s protective barrier and allows the immune system to flood in and destroy the cancer.
Scientists at the Icahn School of Medicine at Mount Sinai have created an experimental immunotherapy that approaches metastatic cancer from a different angle. Rather than attacking cancer cells directly, the treatment focuses on the cells that surround and protect them.
The research, published in the January 22 online issue of Cancer Cell, a Cell Press Journal, tested the strategy in aggressive preclinical models of metastatic ovarian and lung cancer. The findings suggest a promising new direction for treating advanced solid tumors that have resisted existing therapies.
Know more: https://www.sciencedaily.com/releases/2026/01/260128075332.htm
